Objective. Auto-antibodies directed to dsDNA (anti-dsDNA) are used in diagnosis and follow-up for SLE. However, multiple assays are used. The objective of this study was to determine the best-performing assays, especially in prediction of exacerbations.
Introduction
SLE is a multisystemic autoimmune disease. The presence of many auto-antibodies is a hallmark of this disease. In particular, auto-antibodies directed to dsDNA (anti-dsDNA) are characteristic [1] . These antibodies are important for diagnosis, as well as in monitoring disease activity [2, 3] . However, many assays are available, and it is still uncertain which assay shows the highest specificity and predictive value for exacerbations. Well-known assays are radioimmunoassays based on immunoprecipitation (Farr assay), IIF assays using the haemoflagellate Crithidia luciliae (CLIFT) and ELISA or automated fluorescence immunoassays, such as enzyme-labelled anti-isotype assay (EliA) [1] . These assays show significant differences concerning the class, avidity, complementfixing ability, antigenic specificity and cross-reactive pattern of the antibodies that are detected [1, 4] . Nowadays, more often EliA is used because this is an automated assay, does not use radioactive materials and takes less time. A few studies have demonstrated equal sensitivity and specificity [47] , but only two studies have investigated this assay longitudinally in relatively small numbers of patients [8, 9] . As part of the process of re-evaluating our laboratory procedures for anti-dsDNA testing, we compared seven well-known assays, including the Farr assay and EliA, in patients with active nephritis. Thereafter, we used the two best-performing assays to determine sensitivity and specificity in active as well as quiescent disease. Finally, we analysed samples longitudinally to determine the predictive value of an increase in anti-dsDNA levels in patients with and without exacerbations with different types of disease manifestations.
Methods

Patients
To compare seven different assays to detect levels of antidsDNA in active LN, we used all available serum samples of patients who participated in the first or second Dutch Lupus Nephritis Study in our centre. All patients were 1870 years old, fulfilled four or more ACR criteria for SLE [10] and had biopsy-proven proliferative LN. Patient characteristics have been described previously [11, 12] . Two samples per patient were included, resulting in 58 samples from 29 patients.
Next, all consecutive serum samples sent to our laboratory for determination of anti-dsDNA levels were measured from 1 January 2012 to 31 October 2012 by both Farr assay and EliA, because these detected the highest number of positive results during active nephritis. Every patient was included at only one time point. During this 10 month period, 152 SLE patients with quiescent disease, defined as SLEDAI 4 4, 40 SLE patients with active disease, defined as SLEDAI > 4, and 214 disease controls were included. This control group consisted of 25 patients with RA, 20 MCTD, 19 non-specific joint complaints, 18 incomplete lupus, 16 spondylartropathy, 14 colitis or autoimmune hepatitis, 11 SS, 11 RP, 6 APS, 6 undifferentiated autoimmune diseases, 5 infectious diseases, 3 scleroderma and 60 other diseases.
Finally, using longitudinal analyses, we investigated the predictive value of an increase in anti-dsDNA levels as measured by the Farr assay and EliA in patients with and without exacerbations. Seventeen SLE patients with an exacerbation during the period from 2009 to 2012 were included retrospectively, as well as 17 patients who participated in the LN study, from whom samples were available prior to the exacerbation. Increases in anti-dsDNA levels as measured by the Farr assay and EliA were compared using a serum sample 6 and/or 3 months before exacerbation and a serum sample during exacerbation. An increase of 25% and at least 10 IU/ml was defined as a positive increase [8] . Furthermore, complement levels of C3 and C4 were obtained from medical records. Decreased complement was defined as C3 <0.9 g/l and/ or C4 <0.1 g/l. A decrease of 10%, resulting in at least C3 levels <0.9 g/l and/or C4 levels <0.1 g/l, was defined as a possible clinically significant decrease.
For the control group, samples were collected from the same patients as those who were included with an exacerbation (see above) 1 year before exacerbation. Samples from 22 of these 34 patients were available. During this period, all these patients had quiescent disease. From our SLE database, another control group was extracted consisting of 20 age-and sex-matched patients. Samples were chosen from the same time period, and all these patients had quiescent disease. The studies (LN study and biobanking of SLE patients) were approved by the Institutional Review Board of the University Medical Center of Groningen. The approval included the present study. Informed consent was obtained from all SLE patients at study initiation. To make further use of medical data from other patients, an objection register is operational in our hospital.
Assays
Seven assays were used to investigate the most sensitive assay in active LN, as follows: RIA Farr assay (Siemens Healthcare Diagnostics, the Hague, The Netherlands), Farrzyme ELISA (The Binding Site, Birmingham, UK), automated anti-dsDNA on Alegria (Orgentec Diagnostika, Mainz, Germany), automated EliA antidsDNA assay (ThermoFisher Scientific, Nieuwegein, The Netherlands), EuroImmun anti-dsDNA-NcX ELISA (Euroimmun, Lü beck, Germany), Menarini anti-dsDNA ELISA (Menarini Diagnostics, Firenze, Italy) and ANA III plus Luminex assay (Zeus Scientific, Branchburg, NJ, USA).
In all other analyses, only the Farr assay and EliA were used. The imprecision of these two assays was calculated using the control serum samples used in the assays and was 7.2 and 9.1%, respectively.
Data analyses
Data are presented as the median and interquartile range, because most data were not normally distributed. Sensitivity and specificity and predictive value data were www.rheumatology.oxfordjournals.org calculated from 2 Â2 contingency tables using SPSS 22.0 (IBM, Chicago, IL, USA).
Results
Comparing seven different assays during active LN
Seven different assays were compared in 58 samples from 29 patients with active LN [23 (79%) female, median age 39 years, interquartile range 2650 years].
As shown in supplementary Table S1 , available at Rheumatology Online, anti-dsDNA measured by the Farr assay as well as EliA were most frequently positive during active nephritis (95%). In three (10%) patients with active nephritis, levels of anti-dsDNA were negative using the Farr assay and/or EliA. All three patients had positive levels of anti-dsDNA previously and were using immunosuppressive medication at the time when these samples were collected (see also supplementary Table S2 , available at Rheumatology Online).
Comparing Farr assay and EliA in consecutive patients
Consecutive patients were measured from 1 January 2012 to 31 October 2012 with both the Farr assay and EliA, resulting in 152 SLE patients with quiescent disease, 40 SLE with active disease and 214 disease controls (see Fig. 1 and supplementary Table S3 , available at Rheumatology Online). In general, levels obtained by EliA were lower compared with those values obtained by the Farr assay. In active disease, the sensitivity of both techniques was equal (95 vs 93%). In quiescent disease, the specificity of EliA was much higher (91 vs 53%).
Using EliA, only 19/214 (9%) controls had positive antidsDNA levels. Ten of these 19 controls were also positive using the Farr assay. Sixteen of these patients were diagnosed with another systemic auto-immune disease. In addition, one patient was diagnosed with common variable immune deficiency and two patients used anti-TNF treatment. Further characteristics are presented in supplementary Table S4 , available at Rheumatology Online.
Using the Farr assay, 101/214 (47%) controls had positive anti-dsDNA levels. Characteristics of the control patients positive only by the Farr assay (91 controls/ 214 = 43%) and negative by EliA (10 controls/214 = 5%) are presented in supplementary Table S5 , available at Rheumatology Online. The median level as measured by the Farr assay was 21 IU/ml (interquartile range: 1450 IU/ ml), which was lower compared with active SLE patients but comparable to SLE patients with quiescent disease. Most of these controls suffered from other systemic autoimmune diseases or incomplete SLE. Furthermore, a substantial proportion of these patients used anti-TNF treatment (21/91= 23%).
Comparing Farr assay and EliA longitudinally
In total, 34 patients with an exacerbation were included. Seventeen (50%) patients had active LN, and 17 (50%) patients had other non-nephritic manifestations, including new rash (n = 4), haematological abnormalities (n = 4), arthritis (n = 3), pleuritis (n = 3), cerebral vasculitis (n = 1), myositis (n = 1) and vasculitis (n = 1). Samples were obtained 6 months (median 6.0 months, interquartile range: 5.17.3 months) and 3 months (median 3.1 months, interquartile range: 2.33.4 months) before exacerbation. Both methods demonstrated a 25% increase in anti-dsDNA levels in $70% of the patients using samples from 6 months before exacerbation (see Table 1 and supplementary Fig. S1 , available at Rheumatology Online). This was slightly less, $60%, using the samples from 3 months before exacerbation. In the event of active nephritis, a 25% increase was found in 82% using the Farr assay and in 93% using EliA. Comparing EliA and the Farr assay, EliA seemed to perform less well in predicting non-nephritic flares, but this was not significant (43 vs 66%, P = 0.2).
FIG. 1 Anti-dsDNA levels using Farr (A) and enzymelabelled anti-isotype assay (B) in consecutive patients
Absolute values in disease controls and SLE patients with quiescent and active disease, defined as a SLEDAI > 4. Sensitivity and specificity are depicted in supplementary  Table S3 .
Complement levels were also recorded (see supplementary Table S6 , available at Rheumatology Online). During active nephritis, all patients with a decrease in complement levels also had a 25% increase in antidsDNA levels. In patients with non-nephritic exacerbations, five patients had no accompanying significant increase in anti-dsDNA.
As a control group, samples from the same patients as those who had an exacerbation were collected 1 year before exacerbation. Samples from 22 patients were available. During this period, all patients had quiescent disease. In only two (9%) patients, a 25% increase was found using both techniques. As another control group, 20 age-and sex-matched SLE patients with quiescent disease were included. Of these patients, two (10%) had a 25% increase in anti-dsDNA antibodies using the Farr assay and three (15%) patients using EliA, with rather low absolute values. Thus, in total 42 patients with persistent quiescent disease were studied, of whom a 25% increase in the level of anti-dsDNA was found in four (10%) patients using the Farr assay and in five (12%) patients using EliA. Additionally, complement levels were obtained. Of these 42 patients, 4 (10%) patients had a 10% decrease of complement levels resulting in C3 <0.9 g/l and/or C4 <0.1 g/l. Two of these patients also had a 25% increase of anti-dsDNA levels.
Discussion
In the present study comparing seven different assays, we demonstrated that positive dsDNA antibodies were found during active nephritis most often when using the Farr assay or EliA. Further analyses were done using these two assays, demonstrating that while the sensitivity of both assays was equal in active disease, EliA had a higher specificity. Furthermore, in predicting disease activity during follow-up, a very important utility of a useful biomarker, both techniques performed equally.
Measurement of anti-dsDNA levels is essential in diagnosis and follow-up of SLE patients. Many assays are available, but nowadays an assay should be quick, safe, reliable and as inexpensive as possible. In SLE, it is important that during active disease, especially active nephritis, such a biomarker is sensitive to detect change over time. Therefore, we chose to compare seven assays during active nephritis, looking for the assay with of the most often positive anti-dsDNA levels, which we revealed to be the Farr assay and EliA. Thereafter, sensitivity and specificity were assessed in consecutive patients. Sensitivity in active patients was equal comparing the Farr assay with EliA (93 vs 95%). In patients with quiescent disease, anti-dsDNA positivity was 71% using the Farr assay and only 41% using EliA. Furthermore, EliA: enzyme-labelled anti-isotype assay; IQR: interquartile range.
www.rheumatology.oxfordjournals.org specificity was higher using EliA compared with the Farr assay (91 vs 53%). As anti-dsDNA positivity should be low in quiescent disease and disease controls, these findings favour the use of EliA.
Compared with previous studies [47, 9] , we found comparable sensitivity and specificity, except for specificity of the Farr assay, which was much lower in our study. This might be attributable to the use of other controls, including patients with incomplete lupus and patients who use anti-TNF treatment. Importantly, some biologics, especially anti-TNF, can induce anti-dsDNA, which results in false-positive outcomes [13] . Therefore, measurements of anti-dsDNA in patients on biologic treatments should be interpreted with caution.
A biomarker should predict flares in SLE. We tested the Farr assay and EliA in 34 SLE patients with flares, which showed equally in 75 and 69% of patients an increase of 25% in anti-dsDNA levels. Our findings are in line with a previous study, in which 22 exacerbations were explored using the Farr assay and EliA [8] . Enocsson et al. [9] carried out longitudinal measurements in only nine patients using EliA and stated that in seven patients (78%) a 25% increase in dsDNA was found. Both studies did not find a correlation with the type of exacerbation. Given that we included more patients with exacerbations, we did find more often an increase before nephritis (Farr: 82% and EliA: 93%) compared with non-nephritic flares (Farr: 66% and EliA: 43%). Unfortunately, we cannot discuss the performance of other assays, because we included only the Farr assay and EliA in our longitudinal analyses. During active nephritis, complement levels do not have additional value besides measurement of anti-dsDNA, because all patients with a decrease in complement also have an increase in anti-dsDNA. However, during nonnephritic flares, some patients showed a decrease in complement with no increase in anti-dsDNA. Thus, for clinicians, it is important to realize that presumably regardless of which assay is used, non-nephritic flares in particular are not always accompanied by an increase in anti-dsDNA levels, but some of these patients do have decreased complement levels.
Of course, changes in anti-dsDNA are dependent on the chosen time period prior to exacerbation. We used 3 and 6 months prior to exacerbation. These time periods were based on data from a prospective study, in which changes in anti-dsDNA levels were observed between 0 and 7 months (median 2.1 months) before exacerbation [14] .
Conclusion
This retrospective analysis of a large cohort of patients revealed that anti-dsDNA measured by EliA is a useful biomarker in SLE, because we demonstrated a very good specificity, a good sensitivity for active disease and a good predictive value for exacerbation. The results of EliA were comparable to those of the Farr assay, but EliA has the advantages of being automated, fast and non-radioactive. www.rheumatology.oxfordjournals.org
